Equine Lymphosarcoma

Other Names

Equine lymphoma; lymphoid neoplasia; malignant lymphoma; lymphoblastic lymphoma.

What is Equine Lymphosarcoma?

Equine lymphosarcoma is the most common cancer diagnosed in horses and ponies, accounting for between 30 and 50 per cent of all equine neoplasia. Despite this, it remains a relatively rare condition in the general horse population. The disease involves the malignant proliferation of lymphocytes — the white blood cells responsible for immune function — and can affect virtually any organ system in the body.

There are four recognised anatomical forms: multicentric (generalised), alimentary (gastrointestinal), mediastinal (chest cavity), and cutaneous (skin). The multicentric form is the most frequently encountered in clinical practice, while the cutaneous form carries the most favourable prognosis. Horses of any age can be affected, though the disease is more commonly diagnosed in animals between four and fifteen years of age.

Unlike some cancers, equine lymphosarcoma does not have a clearly defined cause, which makes it one of the more challenging diagnoses in equine medicine. Early recognition matters enormously because the disease is ultimately progressive, and treatment options — while limited — are most effective when initiated early.

Causes

The precise cause of equine lymphosarcoma remains unknown. There is currently no definitive evidence of a viral origin in horses, unlike in cattle where bovine leukaemia virus is a known cause of a similar condition. Genetic predisposition may play a role, and there is some suggestion that immune dysregulation contributes to the development of malignant lymphoid cells.

Environmental factors such as prolonged exposure to certain toxins or feed contaminants have been proposed as potential contributing factors, but no robust causal link has been established. Breed predispositions have been informally noted — Thoroughbreds and Standardbreds appear to be somewhat over-represented in case reports — but this may partly reflect reporting bias given their prevalence in equine populations.

Symptoms and Signs

Clinical signs vary considerably depending on the anatomical form of the disease, the organs involved, and the stage of progression. Common presenting signs include:

Progressive, unexplained weight loss despite adequate feeding
Generalised weakness and lethargy
Enlarged lymph nodes palpable along the neck, groin, or behind the jaw
Intermittent fever with no identifiable infectious cause
Ventral oedema — fluid swelling along the belly and lower limbs
Reduced appetite or complete anorexia
Exercise intolerance and poor performance
Colic or diarrhoea in horses with alimentary involvement
Respiratory difficulty when the chest cavity is affected
Multiple firm, non-painful skin nodules in the cutaneous form

The disease frequently mimics other chronic conditions, which is why definitive diagnosis requires laboratory and histopathological confirmation rather than clinical assessment alone.

Diagnosis

Diagnosis involves a combination of clinical examination, haematology, biochemistry, imaging, and biopsy. A complete blood count may reveal anaemia, abnormal lymphocyte counts, or elevated protein levels. Biochemical panels often show hypoalbuminaemia and hyperglobulinaemia, reflecting the body’s abnormal protein metabolism.

Ultrasound of the abdomen and chest is invaluable for identifying enlarged lymph nodes or abnormal masses. Fine needle aspirates of enlarged lymph nodes can provide cytological evidence, though definitive diagnosis relies on tissue biopsy and histopathology. Immunophenotyping — determining whether the malignant cells are T-cell or B-cell in origin — is increasingly used to guide prognosis and treatment planning.

In some horses, peritoneal or pleural fluid analysis reveals neoplastic lymphocytes, which can support the diagnosis without the need for surgical biopsy.

Treatment

There is no cure for equine lymphosarcoma. Treatment aims to slow disease progression, improve quality of life, and extend the horse’s functional lifespan. Corticosteroids — most commonly oral prednisolone or dexamethasone — are the mainstay of palliative therapy and can produce temporary remission, particularly in horses with T-cell lymphoma. Some horses respond well initially and can remain comfortable for months to over a year.

Combination chemotherapy protocols borrowed from small animal oncology have been used in select cases, but cost, practicality, and variable response rates limit their widespread application. Supportive care including nutritional support, anti-inflammatory therapy, and management of secondary complications such as oedema or anaemia forms an important part of the overall plan.

The cutaneous form responds most favourably and may enter prolonged remission with corticosteroid therapy alone.

Prevention

There are no known preventive measures for equine lymphosarcoma given the unclear aetiology. Maintaining good overall health, providing a high-quality diet, minimising chronic stressors, and ensuring regular veterinary check-ups improves the likelihood of early detection. Any horse showing unexplained weight loss, chronic lethargy, or swollen lymph nodes should receive a prompt veterinary assessment.

Prognosis

The prognosis for equine lymphosarcoma is generally poor to grave for the multicentric, alimentary, and mediastinal forms. Mean survival time from diagnosis, even with treatment, is typically weeks to several months. The cutaneous form is the notable exception — horses with skin-only involvement can survive for one to three years or longer with appropriate management.

Euthanasia on humane grounds is often necessary once quality of life deteriorates to a point where suffering cannot be adequately controlled.

When to Call the Vet

Contact your vet promptly if your horse is losing weight despite normal feeding, has persistently swollen lymph nodes, develops unexplained firm skin lumps, shows a recurring fever without obvious cause, or becomes progressively lethargic. Early diagnosis gives the most options, even if those options are ultimately palliative.

Frequently Asked Questions

Can equine lymphosarcoma be cured?

No. There is currently no curative treatment. Management with corticosteroids can produce remission and extend quality life, but the condition is ultimately terminal in the vast majority of cases. The cutaneous form is the exception and may be managed successfully for extended periods.

Is equine lymphosarcoma contagious to other horses?

No. Equine lymphosarcoma is not contagious and cannot be transmitted between horses through contact, shared water sources, or equipment. Unlike bovine lymphoma, there is no known viral agent responsible in horses.

How quickly does equine lymphosarcoma progress?

Progression varies widely between individuals and depends heavily on which form of the disease is present. Some horses deteriorate over weeks; others remain manageable for a year or more, particularly with the cutaneous form. Regular monitoring by your vet is essential to track progression in your specific horse.

Can young horses get lymphosarcoma?

Yes, although it is less common in young horses. The disease most frequently affects adults between four and fifteen years of age, but cases in horses under three years have been documented.

For further information, the British Equine Veterinary Association (BEVA) provides guidance on equine oncology and diagnostic protocols.